Intrathecal administration of anti-HER2 treatment for the treatment of meningeal carcinomatosis in breast cancer: A metanalysis with meta-regression

•Intrathecal anti-HER2 is a promising treatment option in HER2 positive BC leptomeningeal metastases.•Median overall survival in patients treated with intrathecal trastuzumab 5.7 months.•Tolerable safety profile; no serious adverse events in 90% of cases. Leptomeningeal Metastases (LM) is a turning...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Cancer treatment reviews 2020-08, Vol.88 (9), p.102046-102046, Article 102046
Hauptverfasser:	Zagouri, Flora, Zoumpourlis, Panagiotis, Le Rhun, Emilie, Bartsch, Rupert, Zografos, Eleni, Apostolidou, Kleoniki, Dimopoulos, Meletios-Athanasios, Preusser, Matthias
Format:	Artikel
Sprache:	eng
Schlagworte:	Cerebrospinal fluid HER2 positive Leptomeningeal Metastases Life Sciences Trastuzumab
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!